Using Cyclosporin A to Improve Cancer Antibody Therapy
Author Information
Author(s): J.A. Ledermann, R.H.J. Begent, K.D. Bagshawe, S.J. Riggs, F. Searle, M.G. Glaser, A.J. Green, R.G. Dale
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Can Cyclosporin A suppress the formation of human antimouse antibodies (HAMA) in patients receiving repeated doses of antitumour antibodies?
Conclusion
Cyclosporin A allows for more effective repeated therapy with antitumour antibodies by reducing HAMA levels.
Supporting Evidence
- Patients receiving Cyclosporin A had significantly lower HAMA levels compared to those who did not.
- Up to four times as many doses of antitumour antibody could be given with Cyclosporin A.
- Patients with lower HAMA levels showed better accumulation of the antibody in tumors.
Takeaway
This study found that giving a medicine called Cyclosporin A helps cancer patients receive more treatments with special antibodies without their bodies fighting them off.
Methodology
Six patients with CEA-producing tumors received repeated doses of a radiolabelled antibody and Cyclosporin A over several weeks, with HAMA levels measured before and after treatment.
Limitations
The study involved a small number of patients and was preliminary in nature.
Participant Demographics
Patients had locally recurrent or metastatic CEA-producing tumors and had previously failed conventional therapy.
Want to read the original?
Access the complete publication on the publisher's website